Zenas BioPharma (NASDAQ:ZBIO) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Zenas BioPharma (NASDAQ:ZBIO) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Evercore ISI assumed coverage on shares of Zenas BioPharma in a research note on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective for the company. Morgan Stanley cut shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $37.00 to $19.00 in a research report on Monday, January 5th. Finally, Citigroup increased their target price on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Stock Up 23.0%

Shares of NASDAQ:ZBIO opened at $19.78 on Friday. The company’s fifty day moving average is $34.71 and its two-hundred day moving average is $24.27. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. Zenas BioPharma has a 1-year low of $5.83 and a 1-year high of $44.60. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.80 and a beta of -1.45.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Insider Buying and Selling

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 50,000 shares of Zenas BioPharma stock in a transaction on Wednesday, January 7th. The stock was purchased at an average cost of $16.38 per share, for a total transaction of $819,000.00. Following the completion of the purchase, the chief executive officer directly owned 316,155 shares of the company’s stock, valued at $5,178,618.90. The trade was a 18.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 100,000 shares of company stock valued at $1,639,000 in the last quarter. Insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP grew its holdings in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Millennium Management LLC acquired a new position in Zenas BioPharma in the third quarter valued at about $1,595,000. Bank of America Corp DE grew its stake in Zenas BioPharma by 5.8% during the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after buying an additional 818 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Zenas BioPharma by 12.2% during the third quarter. Alliancebernstein L.P. now owns 18,350 shares of the company’s stock worth $407,000 after buying an additional 1,990 shares in the last quarter. Finally, Creative Planning bought a new position in shares of Zenas BioPharma in the third quarter valued at approximately $264,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.